

Parallel

**Proposed Board of Directors
for new Parallel
Biographies - July 2021**

William “Beau” Wrigley Jr. – Chairman and CEO, Parallel



Beginning his career with the William Wrigley Jr. Company in 1985, Beau Wrigley served in multiple roles before becoming Chairman, President and CEO in 1999. He was the fourth-generation member of the Wrigley family to lead the Wm. Wrigley Jr. Company, a global leader in confections founded in 1891. Under Beau’s leadership prior to the company being sold to Mars Incorporated in 2008, the Wrigley Company tripled in size and expanded its reach to consumers in 180 countries.

Currently, Beau is Chairman and CEO of Wrigley Management Inc., a family office, and WWJr. Enterprises Inc., an investment company. Beau also is Co-Founder and Chairman of Higi, a wellness and incentive reward platform.

Beau has served on numerous boards, including Hyatt Hotels Corporation, the J. M. Smucker Company, as well as private and not-for-profit organizations such as the Everglades Foundation. Through his passion for ocean conservation, he created and funded the Ocean Health Index (OHI), the first comprehensive global measurement of ocean health.

A graduate of Duke University with a B.A. in Economics in 1985, Beau attended the Wharton School of Business Advanced Management Program in 1994. Beau is a 1997 Henry Crown Fellow of the Aspen Institute and a member of the Aspen Global Leadership Network.

Parallel

Phil Harris – General Counsel, Parallel



Throughout his legal career, Phil Harris has represented large companies in substantial and complex product liability, mass tort, and commercial cases.

In addition to his experience as a trial attorney, Phil has conducted internal investigations for large, regulated businesses and institutions. As a partner at several global law firms, most recently Jenner & Block, he served on their management and diversity committees and as a practice area leader.

For 25 years, before becoming Vice President and General Counsel for Northwestern University, he served on Northwestern’s Board of Trustees. As a Trustee, he served on two presidential search committees and also chaired important task forces for the University on diversity and inclusion. Additionally, he led a programmatic review of the Board’s effectiveness in its governance and oversight function.

Phil is AV Peer Review Rated, Martindale-Hubbell’s highest peer recognition for ethical standards and legal ability. He is an elected member of the American Law Institute and was named a “Leading Law Firm Rainmaker” by Diversity & The Bar magazine.

Phil is a fellow of Leadership Greater Chicago and the Aspen Institute Henry Crown Values Based Leadership Program. He also served on the boards for the Chicago Zoological Society, Mather LifeWays, the Lincoln Park Zoo, the Chicago Children’s Museum, Children’s Memorial Hospital and Foundation, the University of Chicago Hospitals, the Field Museum of Natural History, and the Chicago Humanities Festival.

Phil received his undergraduate degree from Northwestern University in 1980 and his law degree from the University of Chicago Law School in 1983. He is a member of the bar in Illinois and Iowa and is admitted to practice before the Supreme Court and U.S. District Courts in both states, as well as the U.S. Court of Appeals.

Parallel

Marina Bozilenko – Independent Director



Marina Bozilenko has over 30 years of investment banking and other healthcare industry expertise, including raising more than \$30 billion in capital and executing numerous M&A transactions. She currently serves as Strategic Advisor to William Blair & Company, a firm she joined in 2010 as Head of Biotech & Pharma and Managing Director.

Prior to that, she worked at Bear, Stearns & Co. Inc. as a senior managing director in the healthcare group, at Bank of America Securities as a managing director and head of biotechnology, and at Vector Securities International, where she was a partner. Marina was also a principal at Kidd & Company, a private-equity firm.

She received her B.A. in molecular biology and M.A. in economic history from the University of Chicago. Ms. Bozilenko is currently a Director of Biothea Pharma, a biotechnology company, and NeuroNetworks Fund (NNF), a non-profit organization focused on therapies for autism, epilepsy, schizophrenia and related disorders. She also serves on the Advisory Board of Arctic Aurora Life Sciences, a Swedish healthcare-focused investment fund.

Parallel

Kevin Douglas, M.D. – Independent Director



Kevin Douglas, M.D. is a biopharmaceutical professional with more than 15 years of industry expertise in both U.S. and overseas markets. He began his career in the pharmaceutical industry with Sanofi Aventis before moving on to UCB, a global biopharma company focusing on severe diseases in the Central nervous system (CNS) and Immunology as a Medical Science Liaison. In this role, he supported the launch and U.S. FDA approval of a monoclonal antibody for the treatment of Crohn's Disease and Rheumatoid Arthritis.

Joining UCB's global team as an Associate Director of Global Medical Affairs, Kevin transitioned to Brussels, Belgium, where he led the Gastroenterology Global Medical Affairs team in 2011. His team rallied efforts to re-submit an EMEA regulatory application for approval of a new indication in Crohn's Disease and Ulcerative Colitis before taking a role in Global Clinical Development as an Associate Medical Director of Immunology Practice.

Kevin repatriated to the U.S. in 2014, joining AbbVie, Inc., a publicly-traded, research-based global biopharmaceutical company with over \$45 billion net revenue. Currently, Kevin serves as a Medical Director of U.S. Rheumatology and as a Study Designated Physician/Therapeutic Medical Director, overseeing Phase IIIB studies in the clinical trial program.

Kevin has served on several external expert advisory boards, both globally and in the U.S. He graduated from the University of Maryland Eastern Shore with a B.S. degree in Biology and holds his M.D. from the Medical College of Ohio (University of Toledo College of Medicine). He is published in numerous medical manuscripts and abstracts at major medical conferences.

Parallel

Sarah Hassan – Independent Director



Sarah Hassan was a founding partner of IM HealthScience (IMH), a privately-held healthcare company located in Boca Raton, FL. Over a ten-year period, as a founding partner, CFO, and member of the company’s Executive Leadership Team, Sarah oversaw the rapid growth of IM HealthScience before the company was acquired by Nestlé HealthScience in 2020.

In her role as CFO, Sarah also worked on product development and was also a co-inventor on several key patents. She successfully negotiated manufacturing contracts to enable viable, marketable products and developed and implemented “go to market” strategies resulting in product profitability. Sarah also oversaw the rebuilding and successful turnaround of the acquired Fiber Choice brand.

Prior to working at IM HealthScience, Sarah was a partner at Caerus Ventures, a boutique venture capital firm with a specialty focus of healthcare. She has also been the Fund Manager of Dynagrow Capital, a \$25-million-dollar fund, since 2010.

Sarah is a graduate of Fairleigh Dickinson University, graduating Cum Laude with her BS in Entrepreneurial Studies and Magna Cum Laude with her MBA in Finance and Pharmaceutical Management. She served on the board of the Unicorn Children’s Foundation (UCF) for many years and remains involved with the organization today. Sarah is of South Asian descent (Pakistan) and a member of the LBGT community.

Parallel

Linda McGoldrick – Independent Director



Linda McGoldrick is a global business strategy leader and policy expert in the health care, life sciences and financial services industries. She has spent her entire 30-year career working at the CEO level, in both senior executive and advisory roles – as a CEO, consultant and international independent board of director to numerous corporations including global healthcare and life sciences companies.

Linda is founder and Chairman of Financial Health Associates International (FHA), a global strategy and board advisory firm that consults with health care, insurance, biotechnology, diagnostic and medical device, pharmaceutical technology, government and digital health not-for-profit organizations. She also served as Worldwide Executive Director of the Drug Information Association as well as National Development Director/Senior Vice President of Marsh McLennan Companies. Linda also served as Chief Operating Officer and Marketing Director for VEOS plc, a reproductive pharmaceutical/device developer. For Kaiser Permanente International (London), she developed the business plan, and launched and grew its European business as Managing Director.

Linda began her career as a strategy consultant in the health care practice of Arthur D. Little, then as Director of Business Development, at Shearson Lehman American Express. She holds a qualification in Cyber Security from the U.S. Naval War College. As a dual U.S. and UK citizen, Linda holds a Management MBA from The Wharton School, University of Pennsylvania; an MSW in Health Care from the University of Pennsylvania; and a BA in Sociology from Ohio Wesleyan University. Linda earned a PhD (abd) in Global Health from WPI-Worcester Polytechnic and holds a Masters Professional Director certification from the American College of Corporate Directors.

She is also a faculty member for the National Association of Corporate Directors and International Corporate Governance Network (ICGN), and is often a speaker on Global Governance and Risk issues.

Linda currently serves on the boards of Delta Dental, Avadim Health, Inc., CompassPathways plc, Project Hope, and numerous other university, ministerial, and civic board appointments.

Parallel

Joe Crouthers – Ceres Director



Joe Crouthers is the Chairman and CEO of Ceres Acquisition Corp, a cannabis focused special purpose acquisition company. He is a cannabis industry investor, entrepreneur, and a former portfolio manager and advisor. He is also a co-founder and Chief Executive Officer of Ceres Group Holdings (CGH), a cannabis focused venture equity firm.

After graduating from Vanderbilt University with a Bachelor of Science, Joe engaged in commodities arbitrage before working at Goldman Sachs for over ten years as a portfolio manager and advisor. He later founded GreenLinc, Inc, a Northern California based cannabis distribution and transportation company, brokering sales of input materials to product manufacturers. Since its founding in late 2016, CGH has completed cannabis brand, ancillary, and international transactions.

Joe currently sits on the board of directors of Fotmer Life Sciences Uruguay, a Uruguayan licensed producer and exporter of medical grade cannabis to legal markets around the world. Joe has also successfully completed Level I and Level II of the Chartered Financial Analyst Program from the CFA Institute.

###